This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wei, J. S. Articles by Khan, J. Search for Related Content PubMed PubMed Citation Articles by Wei, J. S. Articles by Khan, J.

Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma

¹ Advanced Technology Center, Oncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, NIH, Gaithersburg, Maryland; ² Department of Tumour Genetics–B030, German Cancer Research Center, Heidelberg, Germany; ³ Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; ⁴ Department of Internal Medicine, College of Oriental Medicine, Daejeon University, Daejeon, Korea; ⁵ Tumour Bank, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia; and ⁶ Department of Pediatrics, Klinik für Kinderheilkunde der Universität zu Köln, Köln, Germany

Currently, patients with neuroblastoma are classified into risk groups (e.g., according to the Children’s Oncology Group risk-stratification) to guide physicians in the choice of the most appropriate therapy. Despite this careful stratification, the survival rate for patients with high-risk neuroblastoma remains <30%, and it is not possible to predict which of these high-risk patients will survive or succumb to the disease. Therefore, we have performed gene expression profiling using cDNA microarrays containing 42,578 clones and used artificial neural networks to develop an accurate predictor of survival for each individual patient with neuroblastoma. Using principal component analysis we found that neuroblastoma tumors exhibited inherent prognostic specific gene expression profiles. Subsequent artificial neural network-based prognosis prediction using expression levels of all 37,920 good-quality clones achieved 88% accuracy. Moreover, using an artificial neural network-based gene minimization strategy in a separate analysis we identified 19 genes, including 2 prognostic markers reported previously, MYCN and CD44, which correctly predicted outcome for 98% of these patients. In addition, these 19 predictor genes were able to additionally partition Children’s Oncology Group-stratified high-risk patients into two subgroups according to their survival status (P = 0.0005). Our findings provide evidence of a gene expression signature that can predict prognosis independent of currently known risk factors and could assist physicians in the individual management of patients with high-risk neuroblastoma.

This article has been cited by other articles:

				J. S. Wei, P. Johansson, Q.-R. Chen, Y. K. Song, S. Durinck, X. Wen, A. T.C. Cheuk, M. A. Smith, P. Houghton, C. Morton, et al. microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies Clin. Cancer Res., September 1, 2009; 15(17): 5560 - 5568. [Abstract] [Full Text] [PDF]

				K. De Preter, S. De Brouwer, T. Van Maerken, F. Pattyn, A. Schramm, A. Eggert, J. Vandesompele, and F. Speleman Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds Clin. Cancer Res., June 1, 2009; 15(11): 3690 - 3696. [Abstract] [Full Text] [PDF]

				L. J. Lancashire, C. Lemetre, and G. R. Ball An introduction to artificial neural networks in bioinformatics--application to complex microarray and mass spectrometry datasets in cancer studies Brief Bioinform, May 1, 2009; 10(3): 315 - 329. [Abstract] [Full Text] [PDF]

				A. Oberthuer, L. Kaderali, Y. Kahlert, B. Hero, F. Westermann, F. Berthold, B. Brors, R. Eils, and M. Fischer Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR Clin. Cancer Res., October 15, 2008; 14(20): 6590 - 6601. [Abstract] [Full Text] [PDF]

				E. Fredlund, M. Ringner, J. M. Maris, and S. Pahlman High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma PNAS, September 16, 2008; 105(37): 14094 - 14099. [Abstract] [Full Text] [PDF]

				S. Bilke, Q.-R. Chen, J. S. Wei, and J. Khan Whole Chromosome Alterations Predict Survival in High-Risk Neuroblastoma without MYCN Amplification Clin. Cancer Res., September 1, 2008; 14(17): 5540 - 5547. [Abstract] [Full Text] [PDF]

				C. Stock, E. Bozsaky, F. Watzinger, U. Poetschger, L. Orel, T. Lion, A. Kowalska, and P. F. Ambros Genes Proximal and Distal to MYCN Are Highly Expressed in Human Neuroblastoma as Visualized by Comparative Expressed Sequence Hybridization Am. J. Pathol., January 1, 2008; 172(1): 203 - 214. [Abstract] [Full Text] [PDF]

				F. Westermann, K.-O. Henrich, J. S. Wei, W. Lutz, M. Fischer, R. Konig, R. Wiedemeyer, V. Ehemann, B. Brors, K. Ernestus, et al. High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status Clin. Cancer Res., August 15, 2007; 13(16): 4695 - 4703. [Abstract] [Full Text] [PDF]

				A. Schramm, J. Vandesompele, J. H. Schulte, S. Dreesmann, L. Kaderali, B. Brors, R. Eils, F. Speleman, and A. Eggert Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome Clin. Cancer Res., March 1, 2007; 13(5): 1459 - 1465. [Abstract] [Full Text] [PDF]

				Q.-R. Chen, G. Vansant, K. Oades, M. Pickering, J. S. Wei, Y. K. Song, J. Monforte, and J. Khan Diagnosis of the Small Round Blue Cell Tumors Using Multiplex Polymerase Chain Reaction J. Mol. Diagn., February 1, 2007; 9(1): 80 - 88. [Abstract] [Full Text] [PDF]

				C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, et al. Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis Cancer Res., January 1, 2007; 67(1): 32 - 40. [Abstract] [Full Text] [PDF]

				A. Oberthuer, F. Berthold, P. Warnat, B. Hero, Y. Kahlert, R. Spitz, K. Ernestus, R. Konig, S. Haas, R. Eils, et al. Customized Oligonucleotide Microarray Gene Expression-Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification J. Clin. Oncol., November 1, 2006; 24(31): 5070 - 5078. [Abstract] [Full Text] [PDF]

				C. Sima and E. R. Dougherty What should be expected from feature selection in small-sample settings Bioinformatics, October 1, 2006; 22(19): 2430 - 2436. [Abstract] [Full Text] [PDF]

				S. Asgharzadeh, R. Pique-Regi, R. Sposto, H. Wang, Y. Yang, H. Shimada, K. Matthay, J. Buckley, A. Ortega, and R. C. Seeger Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. J Natl Cancer Inst, September 6, 2006; 98(17): 1193 - 1203. [Abstract] [Full Text] [PDF]

				M. Fischer, A. Oberthuer, B. Brors, Y. Kahlert, M. Skowron, H. Voth, P. Warnat, K. Ernestus, B. Hero, and F. Berthold Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome Clin. Cancer Res., September 1, 2006; 12(17): 5118 - 5128. [Abstract] [Full Text] [PDF]

				Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res., June 15, 2006; 66(12): 6050 - 6062. [Abstract] [Full Text] [PDF]

				Z. Wang, Y. Wang, J. Xuan, Y. Dong, M. Bakay, Y. Feng, R. Clarke, and E. P. Hoffman Optimized multilayer perceptrons for molecular classification and diagnosis using genomic data Bioinformatics, March 15, 2006; 22(6): 755 - 761. [Abstract] [Full Text] [PDF]

				M. Bredel, C. Bredel, D. Juric, G. E. Duran, R. X. Yu, G. R. Harsh, H. Vogel, L. D. Recht, A. C. Scheck, and B. I. Sikic Tumor Necrosis Factor-{alpha}-Induced Protein 3 As a Putative Regulator of Nuclear Factor-{kappa}B-Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas J. Clin. Oncol., January 10, 2006; 24(2): 274 - 287. [Abstract] [Full Text] [PDF]

				K.-O. Henrich, M. Fischer, D. Mertens, A. Benner, R. Wiedemeyer, B. Brors, A. Oberthuer, F. Berthold, J. S. Wei, J. Khan, et al. Reduced Expression of CAMTA1 Correlates with Adverse Outcome in Neuroblastoma Patients Clin. Cancer Res., January 1, 2006; 12(1): 131 - 138. [Abstract] [Full Text] [PDF]

				R. Korn, S. Rohrig, S. Schulze-Kremer, and U. Brinkmann Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes Bioinformatics, June 1, 2005; 21(11): 2766 - 2772. [Abstract] [Full Text] [PDF]